Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants: What Do They Mean for Patients With Atrial Fibrillation?

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1478-1487

  Hellwig, Thaddaus ^a   Gulseth, Michael ^b  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

anticoagulants; atrial fibrillation; drug drug interactions

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTITHROMBOCYTIC AGENT; APIXABAN; BOCEPREVIR; CLARITHROMYCIN; CLOPIDOGREL; CONIVAPTAN; CYTOCHROME P450; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; DRONEDARONE; GLYCOPROTEIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MIBEFRADIL; NEFAZODONE; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PERMEABILITY GLYCOPROTEIN; POSACONAZOLE; QUINIDINE; RIFAMPICIN; RIVAROXABAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; GRAPEFRUIT JUICE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; STOMACH PH;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG-DRUG INTERACTIONS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MORPHOLINES; P-GLYCOPROTEIN; PYRAZOLES; PYRIDINES; PYRIDONES; THIOPHENES;

EID: 84889058769     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013504741     Document Type: Review

References (37)

1. Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA. 2001;285:2370-2375.
2. Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation. 2006;114:e257-e354.
3. Lin P.Reviewing the reality: why we need to change.Eur Heart J. 2005;7:E15-E20.
4. Nutescu E,Chuatrisorn I,Hellenbart E.Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.J Thromb Thrombolysis. 2011;31:326-343.
5. Princeton, NJ: Bristol Myers Squibb; 2010:.
6. Deedwania P,Huang GW.An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.Core Evid. 2012;7:49-59.
7. Kubitza D,Becka M,Voith B,Zuehlsdorf M,Wensing G.Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.Clin Pharmacol Ther. 2005;78:412-421.
8. Kubitza D,Becka M,Wensing G,Voith B,Zuehlsdorf M.Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects.Eur J Clin Pharmacol. 2005;61:873-880.
9. Raghavan N,Frost CE,Yu Z,et al.Apixaban metabolism and pharmacokinetics after oral administration to humans.Drug Metab Dispos. 2009;37:74-81.
10. Stangier J,Clemens A.Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Clin Appl Thromb Hemost. 2009;15:9S-16S.
11. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2013:.
12. Titusville, NJ: Janssen Pharmaceuticals Inc; 2013:.
13. Princeton, NJ: Bristol Myers Squibb, Pfizer Inc; 2012:.
14. Granger CB,Alexander JH,McMurray J,et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011;365:981-992.
15. Leucuta SE,Vlase L.Pharmacokinetics and metabolic drug interactions.Curr Clin Pharmacol. 2006;1:5-20.
16. US Food and Drug Administration Advisory Committee Briefing Document: Dabigatran etexilate. Boehringer Ingelheim Pharmaceuticals, Inc. August2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterial/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf. Accessed September 10, 2013.
17. US Food and Drug Administration Clinical Review. Dabigatran etexilate. Boehringer Ingelheim Pharmaceuticals, Inc. August2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterial/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed September 10, 2013.
18. Christians U,Schmitz V,Haschke M.Functional interactions between P-glycoprotein and CYP3A in drug metabolism.Expert Opin Drug Metab Toxicol. 2005;1:641-654.
19. Alexander JH,Lopes RD,James S,et al.Apixaban with antiplatelet therapy after acute coronary syndrome.N Eng J Med. 2011;365:699-708.
20. Mendell J,Lee F,Chen S,Worland V,Shi M,Samama MM.The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.J Cardiovasc Pharmacol. 2013;62:212-221.
21. Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009;361:1139-1151.
22. Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011;365:883-891.
23. Goodman SG,Harrington RA,Huber K,et al.Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.Circulation. 2009;119:2877-2885.
24. Oldgren J,Wallentin L,Alexander JH,et al.New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.Eur Heart J. 2013;34:1670-1680.
25. Mega JL,Braunwald E,Mohanavelu S,et al.Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.Lancet. 2009;374:29-38.
26. Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.Eur Heart J. 2011;32:2781-2789.
27. Mega JL,Braunwald E,Wiviott SD,et al.Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med. 2012;366:9-19.
28. Gulseth MP,Wittkowsky AK,Fanikos J,et al.Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.Pharmacotherapy. 2011;31:1232-1249.
29. Gnoth MJ,Buetehorn U,Muenster U,Schwarz T,Sandmann S.In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.J Pharmacol Exp Ther. 2011;338:372-380.
30. Weinz C,Schwarz T,Kubitza D,Mueck W,Lang D.Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.Drug Metab Dispos. 2009;37:1056-1064.
31. US Food and Drug Administration Advisory Committee briefing document. Rivaroxaban. Johnson & Johnson Pharmaceutical Research & Development. August2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovasclarandRenalDrugsAdvisoryCommittee/UCM270797.pdf. Accessed September 10, 2013.
32. Lang D,Freudenberger C,Weinz C.In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.Drug Metab Dispos. 2009;37:1046-1055.
33. Kubitza D,Becka M,Zuehlsdorf M,Mueck W.Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.J Clin Pharmacol. 2006;46:549-558.
34. Moore KT,Plotnikov AN,Thyssen A,et al.Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.J Cardiovasc Pharmacol. 2011;58:581-588.
35. Kubitza D,Becka M,Mueck W,Zuehlsdorf M.Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin.J Clin Pharmacol. 2006;46:981-990.
36. Carreiro J,Ansell J.Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict.Expert Opin Investig Drugs. 2008;17:1937-1945.
37. Upreti VV,Song Y,Wang J,et al.Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Clin Pharmacol. 2013;5:59-66.